ACC Congress coverage: the interventional cardiology perspective

Aaysha Cader and Ali Nazmi Calik provide their take on the BHF PROTECT-TAVI trial, presented by Rajesh Kharbanda at ACC.25 in Chicago.

Luis Ortega-Paz interviews Deepak L. Bhatt about the results of the Phase 3 Reverse-it trial which he presented during the ACC.25 in Chicago.

Chiara De Biase interviews Sergio Raposeiras-Roubin about the results of the DapaTAVI trial which he presented during the ACC.25 in Chicago.

Nicola Ryan provides her take on the WARRIOR trial which was presented by Eileen Handberg at ACC.25 in Chicago.

The manuscript for this trial has not been published and all assumptions are based upon the presentation.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2025 Scientific Sessions #ACC25

Charles Fauvel provides his take on the RELIEVE-HF study outcomes presented by Gregg W. Stone at ACC.24 in Atlanta.

Mirvat Alasnag interviews Javed Butler about the EMPACT-MI trial which he presented at ACC.24 in Atlanta. 

Among patients at increased risk for heart failure after acute MI, treatment with empagliflozin did not lead to a significantly lower risk of first hospitalization for heart failure or death from any...

Luis Ortega-Paz interviews C. Michael Gibson about the AEGIS-II primary trial results which he presented at ACC.24 in Atlanta.

ApoA-I post-heart attack showed no reduction in 90-day death or heart attack risk. However, exploratory analysis hints at benefits at one year, suggesting potential for longer-term efficacy.

Alessandro Sticchi interviews Howard C. Herrmann about the primary outcomes from the randomized SMART Trial which he presented at ACC.24 in Atlanta.

Patients with severe aortic stenosis and small aortic annuli, typically female and often underrepresented in clinical trials, are at risk for impaired valvular hemodynamics and associated...

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...